Survey Says: Latuda Beats Competition

June 2011
Pharmaceutical Representative;Jun2011, Vol. 41 Issue 6, p9
The article presents findings of research survey made by DTW Marketing on the probability of a recommended drug from psychiatrists preferring Sunovion Pharmaceutical Inc.'s Latuda from Merck & Co.'s Saphris or Novartis AG's Fenapt in the U.S.


Related Articles

  • Putting the Focus Back on Physician Prescribing.  // Pharmaceutical Representative;Jun2011, Vol. 41 Issue 6, p8 

    The article reports on the findings that only seven brands were above average in terms of usefulness for doctors out of the 70 brands evaluated including AstraZeneca's Symbicort, Merck's Januvia, and AZ's Seroquel XR according to L2's Digital Intelligent Quotient (IQ) index.

  • Treat the Patient, Not the Bottom Line. Shapiro, Aron M.; Abelson, Mark B. // Review of Ophthalmology;Jan2000, Vol. 7 Issue 1, p72 

    Focuses on the factors to be considered in choosing the best medication for a patient in the United States. Role of pharmacoeconomics in identifying the cost effectiveness of the drug; Disadvantage of choosing a less expensive therapeutic alternative; Evaluation on the quality of life in...

  • Children's Meds Become Safer.  // MMR;2/10/2014, Vol. 31 Issue 3, p16 

    The article presents a report published in the December 2013 issue of the journal "Pediatrics" which shows the efficacy of steps taken by makers of cough and cold medicines to reduce adverse drug events in children.

  • P & T PORTFOLIO.  // Drug Topics;2/18/2002, Vol. 146 Issue 4, p16 

    Evaluates the recombinant form of human protein C, Drotrecogin alfa for reducing mortality in adult patients with severe sepsis. Efficacy of the drug; Pharmacology; Warnings related to use.

  • Pressure and Microcirculatory Effects of Treatment with Lercanidipine in Hypertensive Patients and in Vascular Patients with Hypertension. Cesarone, M. R.; ncandela, L. I; Ledda, A.; De Sanctis, M. T.; Steigerwalt, R.; Pellegrini, L.; Bucci, M.; Belcaro, G.; Ciccarelli, R. // Angiology;Aug2000 Supplement, Vol. 51, pS53 

    Evaluates the macrocirculatory and microcirculatory effects of treatment with the antihypertensive agent lercanidipine. Role of lercanidipine in acting both on blood pressure and microcirculation in patients with moderate essential hypertension without vascular disease and those with...

  • Percutaneous Penetration and Disposition of Triclocarban in Man. Scharpf Jr., Lawis G.; Hill, Ira D.; Maibach, Howard I. // Archives of Environmental Health;Jan1975, Vol. 30 Issue 1 

    Determines the effects of percutaneous penetration and disposition of trichlocarbanilide and antibacterial agents in the alteration of body showering in man. Provision of intravenous doses to subjects for the pharmacologic disposition of compound; Effects of intravenous doses on clearing body...

  • Drug Watch.  // Formulary;Dec2005, Vol. 40 Issue 12, p460 

    The article reports on news and developments in pharmaceuticals. A chart is provided on selected dermatologic disorders. Selected literature on calcipotriene/betamethasone, ceftobiprole , dalnavancin and oritavancin is presented. A drug development setback on tazarotene for the treatment of...

  • Failure of Two Commercial Indexes and Spectral Parameters to Reflect the Pharmacodynamic Effect of Desflurane on EEG. Sascha Kreuer; Jörgen Bruhn; Richard Ellerkmann; Stephan Ziegeler; Darius Kubulus; Wolfram Wilhelm // Journal of Clinical Monitoring & Computing;Apr2008, Vol. 22 Issue 2, p149 

    Abstract Objective  We compared two PK/PD models, one with and one without a plateau effect. Bispectral (BIS, Aspect Medical Systems, Natick, MA, version XP) and Narcotrend™ (NCT, MonitorTechnik, Bad Bramstedt, Germany, Version 4.0) indices were used as an...

  • Efficacy and tolerability of propolis special extract GH 2002 as a lip balm against herpes labialis: a randomized, double-blind three-arm dose finding study. Holcová, Simona; Hladiková, Marie // Health (1949-4998);Jan2011, Vol. 3 Issue 1, p49 

    A dose-finding study was performed with respect to the clinical applicability and tolerability of three different concentrations of propolis special extract GH 2002 in a lip balm (0.1%, 0.5% and 1%). The trial was designed as a double- blind, randomized dermatological study in 150 outpatients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics